IN2012DN00969A - - Google Patents
Info
- Publication number
- IN2012DN00969A IN2012DN00969A IN969DEN2012A IN2012DN00969A IN 2012DN00969 A IN2012DN00969 A IN 2012DN00969A IN 969DEN2012 A IN969DEN2012 A IN 969DEN2012A IN 2012DN00969 A IN2012DN00969 A IN 2012DN00969A
- Authority
- IN
- India
- Prior art keywords
- antisense oligonucleotide
- chemotherapeutic agent
- tgf
- beta
- dacarbacine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Abstract
Pharmaceutical composition comprising a chemotherapeutic agent and a TGF-beta antisense oligonucleotide, wherein the antisense oligonucleotide reduces the sensitivity and IC50, respectively, of the cytotoxicity of the chemotherapeutic agent. Preferably, the antisense oligonucleotide is a TGF-beta 1, 2, and/or 3 antisense oligonucleotide and the chemotherapeutic agent is preferably gemcitabine, 5-fluorouracil, temozolomide, dacarbacine, docetaxel, cisplatin, oxaliplatin, tamoxifen, or irinotecan.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09166893 | 2009-07-30 | ||
PCT/EP2010/061152 WO2011012713A1 (en) | 2009-07-30 | 2010-07-30 | Combination of a chemotherapeutic agent and an inhibitor of the tgf-beta system |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN00969A true IN2012DN00969A (en) | 2015-04-10 |
Family
ID=41278403
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN969DEN2012 IN2012DN00969A (en) | 2009-07-30 | 2010-07-30 |
Country Status (17)
Country | Link |
---|---|
US (1) | US8476246B2 (en) |
EP (1) | EP2340308B1 (en) |
JP (1) | JP2013500313A (en) |
KR (1) | KR20120107456A (en) |
CN (1) | CN102712924A (en) |
AU (1) | AU2010277554B2 (en) |
BR (1) | BR112012002102A2 (en) |
CA (1) | CA2769618A1 (en) |
CL (1) | CL2012000247A1 (en) |
CO (1) | CO6511199A2 (en) |
EC (1) | ECSP12011689A (en) |
IL (1) | IL217821A0 (en) |
IN (1) | IN2012DN00969A (en) |
MX (1) | MX2012001244A (en) |
PE (1) | PE20121495A1 (en) |
RU (1) | RU2012107535A (en) |
WO (1) | WO2011012713A1 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4491240B2 (en) * | 2002-01-17 | 2010-06-30 | ザ ユニバーシティ オブ ブリティッシュ コロンビア | Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5, and methods of use thereof |
US20140031250A1 (en) | 2010-10-07 | 2014-01-30 | David Tsai Ting | Biomarkers of Cancer |
TWI454281B (en) * | 2011-10-06 | 2014-10-01 | Nat Univ Tsing Hua | Use of boric acid in boron neutron capture therapy for liver cancer |
WO2013124869A2 (en) * | 2012-02-21 | 2013-08-29 | Amrita Vishwa Vidyapeetham University | The art, method,manner process and system of fibrous bio-degradable polymeric wafers for the local delivery of therapeutic agents in combinations |
WO2014159774A1 (en) * | 2013-03-14 | 2014-10-02 | Teva Pharmaceutical Industries Ltd. | Custirsen treatment with reduced toxicity |
CA2949574C (en) * | 2014-05-23 | 2022-06-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for determining whether a patient will achieve a response after radiation therapy |
WO2016081503A1 (en) * | 2014-11-17 | 2016-05-26 | City Of Hope | Tki permeability enhancers |
EP3314250A4 (en) | 2015-06-26 | 2018-12-05 | Beth Israel Deaconess Medical Center, Inc. | Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells |
WO2017138925A1 (en) | 2016-02-09 | 2017-08-17 | Autotelic Llc | Antitumour combinations of antisense oligonucleotides and anticancer agents |
US9758786B2 (en) | 2016-02-09 | 2017-09-12 | Autotelic, Llc | Compositions and methods for treating pancreatic cancer |
KR20180103816A (en) | 2016-02-09 | 2018-09-19 | 오토텔릭 엘엘씨 | Compositions and methods for treating pancreatic cancer |
WO2018081817A2 (en) | 2016-10-31 | 2018-05-03 | University Of Massachusetts | Targeting microrna-101-3p in cancer therapy |
WO2018089688A1 (en) | 2016-11-09 | 2018-05-17 | Jinjun Shi | Restoration of tumor suppression using mrna-based delivery system |
WO2019157087A1 (en) | 2018-02-06 | 2019-08-15 | The General Hospital Corporation | Repeat rna as biomarkers of tumor immune response |
WO2020186124A1 (en) * | 2019-03-14 | 2020-09-17 | The Research Foundation For The State University Of New York | Modified micrornas and their use in the treatment of cancer |
GB201908012D0 (en) * | 2019-06-05 | 2019-07-17 | Io Biotech Aps | TGF-Beta vaccine |
CN112933238A (en) * | 2021-02-02 | 2021-06-11 | 石河子大学 | Application of substance inhibiting TGF-beta R1 gene expression and cisplatin in treatment and/or prevention of esophageal cancer |
CN113425855B (en) * | 2021-06-28 | 2023-11-07 | 深圳瑞吉生物科技有限公司 | Osteoarthritis pharmaceutical preparation in mRNA dosage form, and preparation method and application thereof |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
JP2547714B2 (en) | 1981-10-23 | 1996-10-23 | モルキユラ− バイオシステムズ インコ−ポレテツド | Oligonucleotide therapeutic agent and method for producing the same |
US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
EP0856579A1 (en) * | 1997-01-31 | 1998-08-05 | BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH | An antisense oligonucleotide preparation method |
US7795232B1 (en) | 2000-08-25 | 2010-09-14 | Genta Incorporated | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers |
US6809118B2 (en) * | 2002-07-25 | 2004-10-26 | Yih-Lin Chung | Methods for therapy of radiation cutaneous syndrome |
JP4682312B2 (en) * | 2003-09-04 | 2011-05-11 | 学校法人日本大学 | TGF-β gene expression inhibitor |
CN1902488A (en) * | 2003-11-13 | 2007-01-24 | 健泰科生物技术公司 | Screening assays and methods of tumor treatment |
WO2005050200A2 (en) * | 2003-11-13 | 2005-06-02 | Genentech, Inc. | Screening assays and methods of tumor treatment |
US20070196269A1 (en) * | 2003-12-19 | 2007-08-23 | Karl-Hermann Schlingensiepen | Pharmaceutical composition |
WO2005084712A2 (en) * | 2004-02-27 | 2005-09-15 | Antisense Pharma Gmbh | Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment |
EP1992360A4 (en) * | 2006-02-01 | 2010-02-17 | Univ Tokyo | Joint use of tgf-beta signal inhibitor and antitumor agent |
JP5322476B2 (en) * | 2008-03-31 | 2013-10-23 | テルモ株式会社 | Liposome production apparatus and liposome production method |
-
2010
- 2010-07-30 MX MX2012001244A patent/MX2012001244A/en active IP Right Grant
- 2010-07-30 AU AU2010277554A patent/AU2010277554B2/en not_active Ceased
- 2010-07-30 PE PE2012000130A patent/PE20121495A1/en not_active Application Discontinuation
- 2010-07-30 WO PCT/EP2010/061152 patent/WO2011012713A1/en active Application Filing
- 2010-07-30 US US13/059,623 patent/US8476246B2/en active Active
- 2010-07-30 CN CN2010800436805A patent/CN102712924A/en active Pending
- 2010-07-30 KR KR1020127005337A patent/KR20120107456A/en not_active Application Discontinuation
- 2010-07-30 IN IN969DEN2012 patent/IN2012DN00969A/en unknown
- 2010-07-30 RU RU2012107535/15A patent/RU2012107535A/en not_active Application Discontinuation
- 2010-07-30 BR BR112012002102A patent/BR112012002102A2/en not_active IP Right Cessation
- 2010-07-30 CA CA2769618A patent/CA2769618A1/en not_active Abandoned
- 2010-07-30 EP EP10737580.0A patent/EP2340308B1/en not_active Not-in-force
- 2010-07-30 JP JP2012522185A patent/JP2013500313A/en active Pending
-
2012
- 2012-01-29 IL IL217821A patent/IL217821A0/en unknown
- 2012-01-30 CL CL2012000247A patent/CL2012000247A1/en unknown
- 2012-02-23 EC ECSP12011689 patent/ECSP12011689A/en unknown
- 2012-02-29 CO CO12035227A patent/CO6511199A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2012001244A (en) | 2012-03-26 |
CO6511199A2 (en) | 2012-08-31 |
US20120027873A1 (en) | 2012-02-02 |
AU2010277554A1 (en) | 2012-03-01 |
JP2013500313A (en) | 2013-01-07 |
CA2769618A1 (en) | 2011-02-03 |
PE20121495A1 (en) | 2012-11-19 |
EP2340308A1 (en) | 2011-07-06 |
AU2010277554B2 (en) | 2015-02-19 |
WO2011012713A1 (en) | 2011-02-03 |
BR112012002102A2 (en) | 2017-05-02 |
CN102712924A (en) | 2012-10-03 |
RU2012107535A (en) | 2013-09-10 |
EP2340308B1 (en) | 2014-12-24 |
ECSP12011689A (en) | 2012-06-29 |
US8476246B2 (en) | 2013-07-02 |
CL2012000247A1 (en) | 2013-07-05 |
IL217821A0 (en) | 2012-03-29 |
KR20120107456A (en) | 2012-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012DN00969A (en) | ||
IL255097A0 (en) | Antimicrobial compounds, pharmaceutical compositions comprising them and uses thereof | |
MX2010003299A (en) | Micromirs. | |
IL284154A (en) | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups, compositions comprising the same and uses thereof | |
IL219700B (en) | Antisense antiviral oligonucleotides, compositions comprising the same and uses thereof | |
MX2011013176A (en) | CHEMICAL MODIFICATION MOTIFS FOR miRNA INHIBITORS AND MIMETICS. | |
HK1216880A1 (en) | Certain triazolopyridines, compositions thereof and their use in the treatment of cancer. | |
IL219912A (en) | Isoxazoline derivatives, their use as pesticides and compositions comprising them | |
IL215799A (en) | Quinazolone compounds, pharmaceutical compositions comprising the same and uses thereof | |
IL219309A (en) | Glycoside derivatives, pharmaceutical compositions comprising them and use thereof for the preparation of medicaments for treating diabetes | |
EP2279008A4 (en) | Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use | |
IL199615A (en) | Urea glucokinase activators, pharmaceutical compositions comprising them and their use | |
EP1976675A4 (en) | Composition, preparation of polycarbosilanes and their uses | |
IL223463A (en) | Urea derivatives , pharmaceutical compositions comprising them and uses thereof | |
IL195245A0 (en) | Substituted prolinamides, production thereof and their use as drugs | |
MX2010009782A (en) | Improved antitumoral treatments. | |
IL218277B (en) | Tetracycline compounds, pharmaceutical compositions comprising them and their use in the manufacture of medicaments for treating or preventing infection | |
IL219134B (en) | Antimicrobial compounds, pharmaceutical compositions and medical devices comprising them and uses thereof | |
ZA201200367B (en) | Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof | |
ZA200905668B (en) | Fabric treatment compositions, their manufacture and use | |
EP2875056A4 (en) | Nitric oxide-releasing diazeniumdiolated polyvinylpyrrolidone-based polymers, and compositions, medical devices, and uses thereof | |
GEP20115158B (en) | Use of ivabradine for obtaining medicaments intended for the treatment of endothelial dysfunction | |
WO2011050994A3 (en) | Closthioamides | |
HK1142631A1 (en) | Anti-tumor drug, medicament, composition, and use thereof | |
WO2014001988A3 (en) | USE OF CTBP1 siRNA FOR THE TREATMENT OF GASTRIC CANCER |